PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02557321 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 23, 2015
Last Update Posted : November 21, 2023
|
Sponsor:
Provectus Biopharmaceuticals, Inc.
Information provided by (Responsible Party):
Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | May 2023 |
| Estimated Study Completion Date : | April 2025 |